Rhythm Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-3.49 Insider Own0.10% Shs Outstand50.40M Perf Week22.65%
Market Cap996.31M Forward P/E- EPS next Y-3.23 Insider Trans-21.27% Shs Float50.28M Perf Month222.34%
Income-175.70M PEG- EPS next Q-0.99 Inst Own99.90% Short Float14.39% Perf Quarter523.19%
Sales13.40M P/S74.35 EPS this Y53.80% Inst Trans0.04% Short Ratio2.99 Perf Half Y233.85%
Book/sh3.88 P/B5.54 EPS next Y7.40% ROA-56.30% Target Price26.67 Perf Year59.97%
Cash/sh5.08 P/C4.23 EPS next 5Y-9.00% ROE-67.70% 52W Range3.04 - 24.44 Perf YTD115.43%
Dividend- P/FCF- EPS past 5Y-4.40% ROI-59.80% 52W High-18.29% Beta2.52
Dividend %- Quick Ratio5.60 Sales past 5Y- Gross Margin92.10% 52W Low556.91% ATR1.99
Employees140 Current Ratio5.60 Sales Q/Q4180.00% Oper. Margin- RSI (14)69.66 Volatility13.18% 16.82%
OptionableYes Debt/Eq0.18 EPS Q/Q-26.70% Profit Margin- Rel Volume0.40 Prev Close21.50
ShortableYes LT Debt/Eq0.18 EarningsAug 02 BMO Payout- Avg Volume2.42M Price19.97
Recom2.10 SMA2037.46% SMA50137.72% SMA200128.05% Volume946,649 Change-7.12%
Aug-08-22Upgrade Goldman Neutral → Buy $28
Aug-05-22Upgrade BofA Securities Underperform → Neutral $8 → $20
Jun-17-22Reiterated Needham Buy $40 → $25
Mar-02-22Resumed Stifel Buy $23
Feb-17-22Upgrade Ladenburg Thalmann Neutral → Buy $15
Dec-08-21Initiated Wells Fargo Overweight $30
Nov-19-21Downgrade Morgan Stanley Overweight → Equal-Weight $50 → $15
Sep-14-21Resumed Goldman Neutral $14
Aug-04-21Downgrade Ladenburg Thalmann Buy → Neutral
Aug-04-21Downgrade BofA Securities Neutral → Underperform $33 → $17
Nov-30-20Downgrade BofA Securities Buy → Neutral $27 → $33
Jan-08-20Initiated Goldman Sell $18
Jul-12-19Upgrade Stifel Hold → Buy $34
Jul-08-19Initiated Canaccord Genuity Buy $35
Mar-13-19Initiated Ladenburg Thalmann Buy $43
Sep-07-18Resumed Morgan Stanley Overweight
Jun-25-18Reiterated Needham Buy $36 → $42
Jun-15-18Reiterated Needham Buy $32 → $36
Oct-30-17Initiated Needham Buy $32
Oct-30-17Initiated BofA/Merrill Buy $30
Aug-08-22 04:01PM  
Aug-03-22 08:00AM  
Aug-02-22 03:51PM  
Jul-28-22 08:00AM  
Jul-27-22 10:01AM  
Jul-26-22 10:01AM  
Jul-22-22 08:39AM  
Jul-21-22 04:03PM  
Jul-20-22 08:00AM  
Jul-18-22 06:00AM  
Jul-13-22 12:15PM  
Jul-12-22 09:12AM  
Jul-08-22 09:00AM  
Jun-27-22 12:05PM  
Jun-22-22 01:24PM  
Jun-17-22 09:41AM  
Jun-16-22 04:02PM  
Jun-13-22 08:00AM  
Jun-02-22 04:01PM  
May-11-22 10:07AM  
May-05-22 04:01PM  
May-04-22 08:00AM  
May-03-22 08:15AM  
May-02-22 08:00AM  
Apr-26-22 08:00AM  
Apr-25-22 03:00PM  
Apr-08-22 08:00AM  
Apr-07-22 02:32PM  
Apr-06-22 08:00AM  
Mar-01-22 04:01PM  
Feb-24-22 08:00AM  
Feb-23-22 08:00AM  
Feb-22-22 08:00AM  
Feb-16-22 08:00AM  
Feb-08-22 04:00PM  
Jan-13-22 09:15AM  
Dec-11-21 05:38AM  
Dec-10-21 09:10AM  
Dec-09-21 09:31AM  
Dec-06-21 08:00AM  
Nov-15-21 07:45AM  
Nov-09-21 04:01PM  
Nov-02-21 07:00AM  
Nov-01-21 04:01PM  
Oct-20-21 08:00AM  
Oct-14-21 04:01PM  
Oct-11-21 02:50PM  
Sep-22-21 10:30AM  
Sep-21-21 07:57PM  
Sep-20-21 07:30AM  
Sep-08-21 04:01PM  
Sep-02-21 04:01PM  
Aug-12-21 07:45AM  
Aug-05-21 12:00PM  
Aug-03-21 07:01AM  
Jul-29-21 08:00AM  
Jul-28-21 04:01PM  
Jul-27-21 08:00AM  
Jul-26-21 05:20PM  
Jul-23-21 10:15AM  
Jul-22-21 08:00AM  
Jul-12-21 09:41AM  
May-27-21 08:00AM  
May-21-21 08:39AM  
May-05-21 08:00AM  
May-03-21 10:55AM  
Apr-13-21 05:49AM  
Apr-09-21 02:16PM  
Apr-07-21 08:00AM  
Mar-20-21 11:30AM  
Mar-09-21 08:00AM  
Mar-01-21 08:00AM  
Feb-24-21 08:30AM  
Feb-12-21 04:12AM  
Feb-10-21 05:23PM  
Feb-04-21 09:49PM  
Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of rare genetic diseases of obesity. The company's lead product candidate is IMCIVREE, a potent melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alstrom syndrome. It is also developing setmelanotide, which is in Phase II clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, Smith-Magenis syndrome obesity, POMC epigenetic disorders, and other MC4R disorders. Rhythm Pharmaceuticals, Inc. has a collaborative research agreement with the Clinical Registry Investigating Bardet-Biedl Syndrome. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Cramer Pamela J.Chief Human Resources OfficerJul 27Sale11.6890110,5242,224Jul 28 04:31 PM
Smith Hunter CChief Financial OfficerJul 01Sale4.087,54730,79257,614Jul 06 06:08 PM
Roberts William T.Chief Accounting OfficerMar 29Sale11.131,02311,3861,477Mar 31 04:31 PM
Shulman JosephChief Technical OfficerFeb 15Sale6.105573,3981,006Feb 15 07:32 PM
Smith Hunter CChief Financial OfficerFeb 15Sale6.108335,08140,161Feb 15 07:31 PM
Chien JenniferEVP, Head of North AmericaFeb 15Sale6.107224,4041,310Feb 15 07:28 PM
Mazabraud YannEVP, Head of InternationalFeb 15Sale6.109345,6971,098Feb 15 07:29 PM